Merck KGaA Strengthens Oncology Portfolio in Commercialization Agreement for Phase III Asset

 

• Pimicotinib (ABSK021) is currently in a global Phase III study in tenosynovial giant cell tumor (TGCT)
• Merck KGaA, Darmstadt, Germany to receive an exclusive commercial license in mainland China, Hong Kong, Macau and Taiwan with option for rest of world
• Pimicotinib has been granted Breakthrough Therapy Designation by China NMPA and U.S. FDA and PRIME Designation by the EMA for treatment of TGCT

https://www.biospace.com/article/releases/merck-kgaa-darmstadt-germany-strengthens-oncology-portfolio-through-commercialization-agreement-with-abbisko-for-phase-iii-asset-pimicotinib/